Didox

SKU: orb1299740

Description

Didox (NSC-324360) is a synthetic inhibitor of ribonucleotide reductase. Research indicates it can diminish markers of oxidative injury in the brain, as observed in studies related to HIV-associated dementia. This small molecule is utilized in research exploring neuroprotection, virology, and redox biology in both cellular and animal models.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 69839-83-4
• MW: 169.13
• Purity: 96.85%
• Formula: C₇H₇NO₄
• SMILES: ONC(=O)c1ccc(O)c(O)c1
• Target: DNA/RNA Synthesis
• Solubility: DMSO:100 mg/mL (591.26 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (23.65 mM)

Bioactivity

• In Vivo:
  Didox treatment of mouse bone marrow-derived mast cells (BMMC) reduced IgE-stimulated degranulation and cytokine production, including IL-6, IL-13, TNF and MIP-1a (CCL3).
• In Vitro:
  Didox induced cell death and that this effect was suppressed by iron supplementation. Cell treatments with didox caused changes of cellular iron content, TfR1 and ferritin levels comparable to those caused by the iron chelators, deferoxamine (DFO) and deferiprone (DFP).Didox is a bidentated iron chelator with two theoretical possible positions for the binding and among them that with the two hydroxyls of the catechol group acting as ligands is the more likely one. The iron chelating property of didox may contribute to its antitumor activity not only blocking the formation of the tyrosil radical on Tyr122 (such as HU) on RRM2 (essential for its activity) but also sequestering the iron needed by this enzyme and to the cell proliferation.
• Cell Research:
  The cells were seeded in a 96-well plate (at a density of 2 × 10^3 cells for HA22T/VGH; 1.5 × 103 cells for HuH7) and exposed to various concentrations of didox and only HA22T/VGH also to hydroxyurea, DFO or DFP (0, 1, 10, 25, 50, 100, 200 and 500 μM) for 24, 48 and 72 h. In other experiments, HA22T/VGH were seeded in 96-well plates and treated with a single dose of didox, HU, DFO, DFP alone or in combination with increasing doses of FAC (25, 50, 100, 200 and 400 μM) for 48–72 h. In other type of treatment, HA22T/VGH cells were or pre-treated for 16 h with a single dose of didox (200 μM) and then treated in combination with FAC (400–800 μM) or directly in combination didox-FAC for 48–72 h.Cell viability was evaluated with an MTT assay. After the indicated time points and treatments, the supernatant was removed and 100 μL of the MTT solution (0.5 mg/mL) diluted in the cell medium was added to the wells. After 3.5 h of incubation at 37 °C and 5% CO2, the MTT medium was removed and 75 μL of DMSO was added to each well. Plates were shaken for 15 min at 37 °C until complete dissolution and absorbance was measured at 540 nm emission wavelengths. Average percentage of cell viability at each concentration was calculated using Microsoft Excel 2016 software.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Didox, DNA Synthesis, DNA/RNA Synthesis, DNASynthesis, inhibit, Inhibitor, NSC324360, NSC-324360, NSC 324360, RNA Synthesis, ribonucleotide reductase(RR), RNASynthesis

Compound Identifiers

PubChem CID

3045